Lower doses of 6-mercaptopurine/azathioprine bring enough clinical efficacy and therapeutic concentration of erythrocyte 6-mercaptopurine metabolite in Japanese IBD patients.
about
Use of thiopurines in inflammatory bowel diseaseMonitoring thiopurine metabolites in korean pediatric patients with inflammatory bowel diseaseA Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab.Ulcerative colitis: prevention of relapse.Monitoring and safety of azathioprine therapy in inflammatory bowel disease.NUDT15, FTO, and RUNX1 genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases.Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide.A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease.Intermittent granulocyte and monocyte apheresis versus mercaptopurine for maintaining remission of ulcerative colitis: a pilot study.Poor recall of prior exposure to varicella zoster, rubella, measles, or mumps in patients with IBD.Measurements of 6-thioguanine nucleotide levels with TPMT and NUDT15 genotyping in patients with Crohn's disease.Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine.The use of infliximab in the prevention of postsurgical recurrence in polysurgery Crohn's disease patients: a pilot open-labeled prospective study.Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring
P2860
Q26824662-CC0859A5-A3A5-435D-B22F-F3C0747AB4CAQ33941619-D144F2C7-2397-47A2-958F-F90D7EABA901Q37373219-B7DA1770-AE04-4652-8D6A-63D3005DA0A4Q38103628-DF9BBFB0-1E9A-46A5-A5D1-09BB9FC41086Q38134756-EF0E785B-0A5F-495A-9423-6933F78E013AQ41080533-F2FEEFD6-48AE-4480-BB8D-6565E006B623Q43202350-AE3FA51D-DBF0-449C-90E3-C2515CFC9A3FQ44039298-FDF0F7EB-8690-4AA5-83AF-2E1D8BEABBD9Q45056874-D3292908-605D-451C-B892-D1FB52DE453AQ45844100-38E3F523-F694-4672-BAC8-A7280E3F194DQ47137978-7FC3DF26-8F20-4732-91BE-03B1BE91E15EQ50448602-E78DA1BF-D398-430D-82ED-24542FF6092CQ51369344-0D927CA7-BCF0-4BBD-866A-70B806F28031Q57817595-AC446265-2A9A-42DE-A15A-C6AFEE280A2C
P2860
Lower doses of 6-mercaptopurine/azathioprine bring enough clinical efficacy and therapeutic concentration of erythrocyte 6-mercaptopurine metabolite in Japanese IBD patients.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Lower doses of 6-mercaptopurin ...... lite in Japanese IBD patients.
@en
Lower doses of 6-mercaptopurin ...... lite in Japanese IBD patients.
@nl
type
label
Lower doses of 6-mercaptopurin ...... lite in Japanese IBD patients.
@en
Lower doses of 6-mercaptopurin ...... lite in Japanese IBD patients.
@nl
prefLabel
Lower doses of 6-mercaptopurin ...... lite in Japanese IBD patients.
@en
Lower doses of 6-mercaptopurin ...... lite in Japanese IBD patients.
@nl
P2093
P2860
P1476
Lower doses of 6-mercaptopurin ...... olite in Japanese IBD patients
@en
P2093
Hiroshi Mae
Ikuko Minami
Kenichi Negishi
Rie Kubota
Shinsuke Funakoshi
Takako Komiyama
Tomoharu Yajima
Toshifumi Hibi
Yasushi Iwao
Yoichi Tanaka
P2860
P304
P356
10.1016/J.CROHNS.2008.05.002
P577
2008-07-03T00:00:00Z